- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Multicentre
- Objective: To assess the impact of monoclonal antibodies and direct antiviral therapies on clinical and virological outcomes in high-risk patients with early mild-to-moderate COVID-19, including sequencing to identify viral population changes and emerging minority variants.
- Number of participants enrolled: 735
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
Other information
Funders/Sponsors:
- French Ministry of Health Prevention
- French Ministry of Higher Education, Research and Innovation
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to